Skip to content

uniQure QURE Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's proceeds from exercises of stock options and other stock issuances?
uniQure (QURE) reported proceeds from exercises of stock options and other stock issuances of $550K in Q1 2026.
How has uniQure's proceeds from exercises of stock options and other stock issuances changed year-over-year?
uniQure's proceeds from exercises of stock options and other stock issuances increased by 245.9% year-over-year, from $159K to $550K.
What is the long-term trend for uniQure's proceeds from exercises of stock options and other stock issuances?
Over 3 years (2021 to 2025), uniQure's proceeds from exercises of stock options and other stock issuances has grown at a 58.6% compound annual growth rate (CAGR), from $2.8M to $11.16M.